文献速递癫痫

早发性癫痫性脑病伴爆发抑制的遗传学与基因型-表型相关性

Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression.
PubMed 文献 · Ann Neurol · 2017-02-14

该研究纳入33例临床诊断为大田原综合征或早期肌阵挛脑病且无皮质发育畸形的患者,对其中28例确认存在爆发抑制的患者进行外显子组测序,在17例(61%)中检出KCNQ2、STXBP1、SCN2A、PNPO、PIGA和SEPSECS的致病变异,KCNQ2占三分之一。除PNPO纯合变异者脑脊液吡哆醛-5-磷酸水平低外,无早期临床或实验室特征可区分不同基因相关病例。

要点

  • 无皮质畸形的爆发抑制型癫痫性脑病中,61%(17/28)可检出致病基因变异。
  • KCNQ2是最常见基因,占该队列约三分之一(10/28)。
  • SEPSECS首次被关联至该电临床综合征。

核心结论

  • 无脑畸形的爆发抑制型癫痫性脑病中,超过60%的病例可通过临床可用检测获得遗传学诊断,KCNQ2占约三分之一。

研究设计与样本

  • 纳入33例临床诊断为大田原综合征或早期肌阵挛脑病且无皮质发育畸形的患者,其中28例确认存在爆发抑制。
  • 对临床评估或研究性癫痫基因面板未明确分子诊断的患者进行研究性外显子组测序。

主要发现

  • 28例确认爆发抑制的患者中,17例(61%)检出预测致病变异:KCNQ2(n=10)、STXBP1(n=2)、SCN2A(n=2)、PNPO(n=1)、PIGA(n=1)、SEPSECS(n=1)。
  • 5例未确认爆发抑制的患者中,3例(60%)检出预测致病变异:STXBP1(n=2)、SCN2A(n=1)。
  • PNPO纯合变异患者脑脊液吡哆醛-5-磷酸水平低。
  • 除PNPO病例外,无早期实验室或临床特征可区分特定基因相关病例与未明确遗传病因病例。

关键数值与推荐

  • 该电临床综合征与SEPSECS的致病变异相关。

临床怎么用

  • 对无皮质畸形的爆发抑制型癫痫性脑病,应开展遗传学检测,KCNQ2为优先考虑基因。
  • 对疑似PNPO相关病例,可检测脑脊液吡哆醛-5-磷酸水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to identify genetic causes of early onset epileptic encephalopathies with burst suppression (Ohtahara syndrome and early myoclonic encephalopathy) and evaluate genotype-phenotype correlations. METHODS: We enrolled 33 patients with a referral diagnosis of Ohtahara syndrome or early myoclonic encephalopathy without malformations of cortical development. We performed detailed phenotypic assessment including seizure presentation, electroencephalography, and magnetic resonance imaging. We confirmed burst suppression in 28 of 33 patients. Research-based exome sequencing was performed for patients without a previously identified molecular diagnosis from clinical evaluation or a research-based epilepsy gene panel. RESULTS: In 17 of 28 (61%) patients with confirmed early burst suppression, we identified variants predicted to be pathogenic in KCNQ2 (n = 10), STXBP1 (n = 2), SCN2A (n = 2), PNPO (n = 1), PIGA (n = 1), and SEPSECS (n = 1). In 3 of 5 (60%) patients without confirmed early burst suppression, we identified variants predicted to be pathogenic in STXBP1 (n = 2) and SCN2A (n = 1). The patient with the homozygous PNPO variant had a low cerebrospinal fluid pyridoxal-5-phosphate level. Otherwise, no early laboratory or clinical features distinguished the cases associated with pathogenic variants in specific genes from each other or from those with no prior genetic cause identified. INTERPRETATION: We characterize the genetic landscape of epileptic encephalopathy with burst suppression, without brain malformations, and demonstrate feasibility of genetic diagnosis with clinically available testing in >60% of our cohort, with KCNQ2 implicated in one-third. This electroclinical syndrome is associated with pathogenic variation in SEPSECS. Ann Neurol 2017;81:419-429.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Olson HE, Kelly M, LaCoursiere CM, et al. Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression. Ann Neurol. 2017. PMID: 28133863. doi:10.1002/ana.24883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。